Real-world first-line use of pertuzumab with different taxanes for human epidermal growth factor receptor 2–positive metastatic breast cancer: A comparative effectiveness study using US electronic health records
Last Updated: Friday, July 17, 2026
According to real-world data from a retrospective comparative analysis study, no statistically significant difference was found in real-world outcomes between patients with HER2-positive metastatic breast cancer treated with paclitaxel/nab-paclitaxel and those treated with docetaxel.